Related papers: Personalized Early Stage Alzheimer's Disease Detec…
Early and accessible detection of Alzheimer's disease (AD) remains a major challenge, as current diagnostic methods often rely on costly and invasive biomarkers. Speech and language analysis has emerged as a promising non-invasive and…
Early diagnosis of Alzheimer's disease (AD) remains a major challenge due to the subtle and temporally irregular progression of structural brain changes in the prodromal stages. Existing deep learning approaches require large longitudinal…
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative disorders in humans. Because a significant percentage of patients have clinical and pathological features of both diseases, it has been…
Deep learning has shown outstanding performance in identifying intricate structures in complex high-dimensional data, especially in the domain of computer vision. The application of deep learning to early detection and automated…
Alzheimer's Disease (AD) and related dementia are a growing global health challenge due to the aging population. In this paper, we present ADMarker, the first end-to-end system that integrates multi-modal sensors and new federated learning…
Speech-based automatic detection of Alzheimer's disease (AD) and depression has attracted increased attention. Confidence estimation is crucial for a trust-worthy automatic diagnostic system which informs the clinician about the confidence…
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder that progressively impairs memory, decision-making, and overall cognitive function. As AD is irreversible, early prediction is critical for timely intervention and…
Early prognosis of Alzheimer's dementia is hard. Mild cognitive impairment (MCI) typically precedes Alzheimer's dementia, yet only a fraction of MCI individuals will progress to dementia, even when screened using biomarkers. We propose here…
Alzheimer's Disease (AD) is a progressive neurodegenerative condition that adversely affects cognitive abilities. Language-related changes can be automatically identified through the analysis of outputs from linguistic assessment tasks,…
Alzheimer's disease (AD) affects 50 million people worldwide and is projected to overwhelm 152 million by 2050. AD is characterized by cognitive decline due partly to disruptions in metabolic brain connectivity. Thus, early and accurate…
As the global burden of Alzheimer's disease (AD) continues to grow, early and accurate detection has become increasingly critical, especially in regions with limited access to advanced diagnostic tools. We propose BRAINS (Biomedical…
Alzheimer's Disease Analysis Model (ADAM) is a multi-agent reasoning large language model (LLM) framework designed to integrate and analyze multimodal data, including microbiome profiles, clinical datasets, and external knowledge bases, to…
Collecting and accessing a large amount of medical data is very time-consuming and laborious, not only because it is difficult to find specific patients but also because it is required to resolve the confidentiality of a patient's medical…
It is acknowledged that the most common cause of dementia worldwide is Alzheimer's disease (AD). This condition progresses in severity from mild to severe and interferes with people's everyday routines. Early diagnosis plays a critical role…
We propose an automatic detection method of Alzheimer's diseases using a gated convolutional neural network (GCNN) from speech data. This GCNN can be trained with a relatively small amount of data and can capture the temporal information in…
Gender bias has been widely observed in speech perception tasks, influenced by the fundamental voicing differences between genders. This study reveals a gender bias in the perception of Alzheimer's Disease (AD) speech. In a perception…
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive memory and cognitive decline, affecting millions worldwide. Diagnosing AD is challenging due to its heterogeneous nature and variable progression. This…
A key issue to Alzheimer's disease clinical trial failures is poor participant selection. Participants have heterogeneous cognitive trajectories and many do not decline during trials, which reduces a study's power to detect treatment…
The cerebrospinal fluid (CSF) of 19 subjects who received a clinical diagnosis of Alzheimer's disease (AD) as well as of 5 pathological controls have been collected and analysed by Raman spectroscopy (RS). We investigated whether the raw…
Alzheimer's disease (AD) is one of the most common public health issues the world is facing today. This disease has a high prevalence primarily in the elderly accompanying memory loss and cognitive decline. AD detection is a challenging…